MedTrace Logo

Pramipexole for Binge Eating Disorder

NCT01106053 · Status: WITHDRAWN · Phase: PHASE3 · Type: INTERVENTIONAL

Last updated 2013-05-06

No results posted yet for this study

Summary

This study is being conducted to evaluate the effects that the drug pramipexole has on mood, food craving, and other behaviors that may be related to binge eating disorder.

Conditions

  • Binge Eating Disorder

Interventions

DRUG

Pramipexole

Pramipexole tablet titrated up to a maximum dosage of 0.5 mg three times daily (1.5 mg/day).

Sponsors & Collaborators

  • Neuropsychiatric Research Institute, Fargo, North Dakota

    lead OTHER

Principal Investigators

  • Kristine J Steffen, PharmD, PhD · Neuropsychiatric Research Institute, Fargo, ND

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-04-30
Primary Completion
2011-07-31

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01106053 on ClinicalTrials.gov